0A8M Stock Overview
A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.64 |
| 52 Week High | US$3.42 |
| 52 Week Low | US$1.46 |
| Beta | -1.4 |
| 11 Month Change | -22.51% |
| 3 Month Change | -34.33% |
| 1 Year Change | -30.72% |
| 33 Year Change | -95.71% |
| 5 Year Change | n/a |
| Change since IPO | -98.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8M | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.4% | 4.2% | 1.7% |
| 1Y | -30.7% | 3.0% | 8.4% |
Return vs Industry: 0A8M underperformed the UK Pharmaceuticals industry which returned 2.5% over the past year.
Return vs Market: 0A8M underperformed the UK Market which returned 8.8% over the past year.
Price Volatility
| 0A8M volatility | |
|---|---|
| 0A8M Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8M's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A8M's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 102 | Josh Disbrow | aytubio.com |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
Aytu BioPharma, Inc. Fundamentals Summary
| 0A8M fundamental statistics | |
|---|---|
| Market cap | US$9.65m |
| Earnings (TTM) | -US$7.28m |
| Revenue (TTM) | US$79.76m |
0.1x
P/S Ratio-1.4x
P/E RatioIs 0A8M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8M income statement (TTM) | |
|---|---|
| Revenue | US$79.76m |
| Cost of Revenue | US$25.50m |
| Gross Profit | US$54.26m |
| Other Expenses | US$61.54m |
| Earnings | -US$7.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 68.03% |
| Net Profit Margin | -9.13% |
| Debt/Equity Ratio | 55.5% |
How did 0A8M perform over the long term?
See historical performance and comparison